Bank of America Corp DE lowered its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 30.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 337,985 shares of the company's stock after selling 144,861 shares during the quarter. Bank of America Corp DE owned about 0.39% of Pediatrix Medical Group worth $4,434,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of MD. American Century Companies Inc. grew its stake in Pediatrix Medical Group by 628.2% during the 4th quarter. American Century Companies Inc. now owns 1,739,323 shares of the company's stock valued at $22,820,000 after purchasing an additional 1,500,485 shares in the last quarter. Oberweis Asset Management Inc. bought a new stake in Pediatrix Medical Group during the 4th quarter valued at $6,122,000. Renaissance Technologies LLC raised its stake in Pediatrix Medical Group by 117.4% during the 4th quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock valued at $11,005,000 after acquiring an additional 453,000 shares in the last quarter. Boston Partners raised its stake in Pediatrix Medical Group by 25.2% during the 4th quarter. Boston Partners now owns 1,956,353 shares of the company's stock valued at $25,922,000 after acquiring an additional 393,600 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Pediatrix Medical Group during the 4th quarter valued at $3,066,000. Institutional investors and hedge funds own 97.71% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently commented on MD. Macquarie boosted their price objective on Pediatrix Medical Group from $19.00 to $20.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. UBS Group dropped their price target on Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a research report on Monday, May 12th. Finally, Truist Financial lowered their target price on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Pediatrix Medical Group has an average rating of "Hold" and a consensus target price of $16.67.
Check Out Our Latest Analysis on MD
Pediatrix Medical Group Stock Performance
Shares of NYSE MD traded down $0.62 during trading hours on Monday, hitting $13.54. 701,755 shares of the company's stock were exchanged, compared to its average volume of 855,191. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $17.67. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.60 and a quick ratio of 1.42. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.28, a PEG ratio of 1.74 and a beta of 1.26. The company's 50-day moving average price is $13.70 and its 200-day moving average price is $14.02.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The company had revenue of $458.36 million during the quarter, compared to the consensus estimate of $451.44 million. During the same quarter last year, the company earned $0.20 EPS. The company's quarterly revenue was down 7.4% on a year-over-year basis. On average, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.
Pediatrix Medical Group Profile
(
Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Recommended Stories
Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
